✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Refametinib is an investigational drug.
There have been 8 clinical trials for Refametinib. The most recent clinical trial was a Phase 2 trial, which was initiated on September 16th 2013.
The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Hepatocellular, and Neoplasms. The leading clinical trial sponsors are Bayer, Samsung Medical Center, and [disabled in preview].
There are four hundred and forty-six US patents protecting this investigational drug and five international patents.
Recent Clinical Trials for Refametinib
|Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma||Samsung Medical Center||Phase 2|
|Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer||Bayer||Phase 1|
|Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)||Bayer||Phase 2|
Top disease conditions for Refametinib
Top clinical trial sponsors for Refametinib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Refametinib||See Plans and Pricing||Compounds and compositions as protein kinase inhibitors||Array BioPharma Inc. (Boulder, CO)||See Plans and Pricing|
|Refametinib||See Plans and Pricing||Antibody drug conjugates||Novartis AG (Basel, CH)||See Plans and Pricing|
|Refametinib||See Plans and Pricing||Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)||BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE)||See Plans and Pricing|
|Refametinib||See Plans and Pricing||Aryl-cyanoguanidine compounds||Bayer Pharma Aktiengesellschaft (Berlin, DE)||See Plans and Pricing|
|Refametinib||See Plans and Pricing||Organic compositions to treat beta-catenin-related diseases||Arrowhead Pharmaceuticals, Inc. (Pasadena, CA)||See Plans and Pricing|
|Refametinib||See Plans and Pricing||Binding molecules specific for HER3 and uses thereof||MEDIMMUNE, LLC (Gaithersburg, MD)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Refametinib||Argentina||AR077975||2029-08-28||See Plans and Pricing|
|Refametinib||Australia||AU2010286569||2029-08-28||See Plans and Pricing|
|Refametinib||Brazil||BR112012004453||2029-08-28||See Plans and Pricing|
|Refametinib||Canada||CA2771775||2029-08-28||See Plans and Pricing|
|Refametinib||Chile||CL2012000340||2029-08-28||See Plans and Pricing|
|Refametinib||China||CN102725283||2029-08-28||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|